(AOF) – Sanofi announces that the 32nd Congress of the International Society of Thrombosis and Hemostasis (ISTH) will be an opportunity to present new data on its hematology product portfolio.
Thus, interim analyzes of data from the long-term phase III extension study Xtend-ed showed that, in adults and children, Altuviiio maintains highly effective protection against bleeding, leading to improvement or stabilization of joint health over a period of two years, with a safety profile comparable to that observed in the initial studies.
The results of additional analyzes will also be presented to the ISTH regarding fitusiran. These support the potential of fitusiran – the first treatment in its class offering uniform protection against bleeding to patients with hemophilia A or B, with or without inhibitors.
“We look forward to collaborating with regulatory bodies to continue to make new therapeutic solutions available to hemophilia patients,” said Dietmar Berger, chief medical officer, global head, development.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.